Vicplas 1H2026 net loss was SGD 3.4 million as revenue rose 15% to SGD 62.4 million

Reuters03-13 18:38
Vicplas 1H2026 net loss was SGD 3.4 million as revenue rose 15% to SGD 62.4 million

Vicplas reported 1H2026 revenue of SGD 62.4 million, up 15%. The company posted a net loss after tax of SGD 3.4 million. Medical devices revenue rose 11% to SGD 39 million, while segment result was a loss of SGD 5.65 million due to higher operating costs tied to the Mexico plant ramp-up and new projects in Singapore and Mexico. Pipes and pipe fittings revenue increased 21% to SGD 23.41 million, and segment result rose 60% to SGD 5.69 million on robust construction activity in Singapore. Group adjusted EBITDA fell 27% to SGD 3.2 million, and CEO Walter Tarca said medical devices revenue is expected to improve as new projects are commercialised and Mexico contributes more, though near-term segment results will remain constrained as utilisation ramps up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vicplas International Ltd. published the original content used to generate this news brief via Singapore Exchange Limited (SGX) (Ref. ID: MC9L7THCBZIP2CST) on March 13, 2026, and is solely responsible for the information contained therein.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment